5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Lower O
limb O
amputation O
: O
See O
boxed O
warning O
( O
5.1 O
) O
* O
Hypotension O
: O
Before O
initiating O
INVOKANA O
, O
assess O
volume O
status O
and O
correct O
hypovolemia O
in O
patients O
with O
renal O
impairment O
, O
the O
elderly O
, O
in O
patients O
with O
low O
systolic O
blood O
pressure O
, O
or O
if O
on O
diuretics O
, O
ACEi O
, O
or O
ARB O
. O

Monitor O
for O
signs O
and O
symptoms O
during O
therapy O
( O
5.2 O
) O
* O
Ketoacidosis O
: O
Assess O
patients O
who O
present O
with O
signs O
and O
symptoms O
of O
metabolic O
acidosis O
for O
ketoacidosis O
, O
regardless O
of O
blood O
glucose O
level O
. O

If O
suspected O
, O
discontinue O
INVOKANA O
, O
evaluate O
and O
treat O
promptly O
. O

Before O
initiating O
INVOKANA O
, O
consider O
risk O
factors O
for O
ketoacidosis O
. O

Patients O
on O
INVOKANA O
may O
require O
monitoring O
and O
temporary O
discontinuation O
of O
therapy O
in O
clinical O
situations O
known O
to O
predispose O
to O
ketoacidosis O
( O
5.3 O
) O
* O
Acute O
kidney O
injury O
and O
impairment O
in O
renal O
function O
: O
Consider O
temporarily O
discontinuing O
in O
settings O
of O
reduced O
oral O
intake O
or O
fluid O
losses O
. O

If O
acute O
kidney O
injury O
occurs O
, O
discontinue O
and O
promptly O
treat O
. O

Monitor O
renal O
function O
during O
therapy O
( O
5.4 O
) O
* O
Hyperkalemia O
: O
Monitor O
potassium O
levels O
in O
patients O
with O
impaired O
renal O
function O
and O
in O
patients O
predisposed O
to O
hyperkalemia O
( O
2.2 O
, O
5.5 O
, O
6.1 O
, O
8.6 O
) O
* O
Urosepsis O
and O
pyelonephritis O
: O
Evaluate O
patients O
for O
signs O
and O
symptoms O
of O
urinary O
tract O
infections O
and O
treat O
promptly O
, O
if O
indicated O
( O
5.6 O
) O
* O
Hypoglycemia O
: O
Consider O
a O
lower O
dose O
of O
insulin O
or O
the O
insulin O
secretagogue O
to O
reduce O
the O
risk O
of O
hypoglycemia O
when O
used O
in O
combination O
with O
INVOKANA O
( O
5.7 O
) O
* O
Genital O
mycotic O
infections O
: O
Monitor O
and O
treat O
if O
indicated O
( O
5.8 O
) O
* O
Hypersensitivity O
reactions O
: O
Discontinue O
INVOKANA O
and O
monitor O
until O
signs O
and O
symptoms O
resolve O
( O
5.9 O
) O
* O
Bone O
fracture O
: O
Consider O
factors O
that O
contribute O
to O
fracture O
risk O
before O
initiating O
INVOKANA O
( O
5.10 O
) O
* O
Increased O
LDL-C O
: O
Monitor O
LDL-C O
and O
treat O
if O
appropriate O
( O
5.11 O
) O
5.1 O
Lower O
Limb O
Amputation O
An O
approximately O
2-fold O
increased O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
associated O
with O
INVOKANA O
use O
was O
observed O
in O
CANVAS O
and O
CANVAS-R O
, O
two O
large O
, O
randomized O
, O
placebo-controlled O
trials O
evaluating O
patients O
with O
type O
2 O
diabetes O
who O
had O
either O
established O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
were O
at O
risk O
for O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

In O
CANVAS O
, O
INVOKANA-treated O
patients O
and O
placebo-treated O
patients O
had O
5.9 O
and O
2.8 O
amputations B-OSE_Labeled_AE
per O
1000 O
patients O
per O
year O
, O
respectively O
. O

In O
CANVAS-R O
, O
INVOKANA-treated O
patients O
and O
placebo-treated O
patients O
had O
7.5 O
and O
4.2 O
amputations B-OSE_Labeled_AE
per O
1000 O
patients O
per O
year O
, O
respectively O
. O

The O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
was O
observed O
at O
both O
the O
100 O
mg O
and O
300 O
mg O
once O
daily O
dosage O
regimens O
. O

The O
amputation B-NonOSE_AE
data O
for O
CANVAS O
and O
CANVAS-R O
are O
shown O
in O
Tables O
2 O
and O
3 O
, O
respectively O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Amputations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the O
toe O
and O
midfoot I-OSE_Labeled_AE
( O
99 O
out O
of O
140 O
patients O
with O
amputations B-OSE_Labeled_AE
receiving O
INVOKANA O
in O
the O
two O
trials O
) O
were O
the O
most O
frequent O
; O
however O
, O
amputations B-OSE_Labeled_AE
involving I-OSE_Labeled_AE
the I-OSE_Labeled_AE
leg I-OSE_Labeled_AE
, O
below O
and O
above O
the O
knee O
, O
were O
also O
observed O
( O
41 O
out O
of O
140 O
patients O
with O
amputations B-OSE_Labeled_AE
receiving O
INVOKANA O
in O
the O
two O
trials O
) O
. O

Some O
patients O
had O
multiple O
amputations B-OSE_Labeled_AE
, O
some O
involving O
both O
lower O
limbs O
. O

Lower B-NonOSE_AE
limb I-NonOSE_AE
infections I-NonOSE_AE
, O
gangrene B-NonOSE_AE
, O
and O
diabetic B-NonOSE_AE
foot I-NonOSE_AE
ulcers I-NonOSE_AE
were O
the O
most O
common O
precipitating O
medical O
events O
leading O
to O
the O
need O
for O
an O
amputation B-NonOSE_AE
. O

The O
risk O
of O
amputation B-NonOSE_AE
was O
highest O
in O
patients O
with O
a O
baseline O
history O
of O
prior O
amputation B-Not_AE_Candidate
, O
peripheral B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
neuropathy B-Not_AE_Candidate
. O

Before O
initiating O
INVOKANA O
, O
consider O
factors O
in O
the O
patient O
history O
that O
may O
predispose O
to O
the O
need O
for O
amputations B-NonOSE_AE
, O
such O
as O
a O
history O
of O
prior O
amputation B-Not_AE_Candidate
, O
peripheral B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
neuropathy B-Not_AE_Candidate
and O
diabetic B-Not_AE_Candidate
foot I-Not_AE_Candidate
ulcers I-Not_AE_Candidate
. O

Counsel O
patients O
about O
the O
importance O
of O
routine O
preventative O
foot O
care O
. O

Monitor O
patients O
receiving O
INVOKANA O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
( O
including O
osteomyelitis B-NonOSE_AE
) O
, O
new O
pain B-NonOSE_AE
or O
tenderness O
, O
sores O
or O
ulcers O
involving O
the O
lower I-NonOSE_AE
limbs I-NonOSE_AE
, O
and O
discontinue O
INVOKANA O
if O
these O
complications O
occur O
. O

5.2 O
Hypotension O
INVOKANA O
causes O
intravascular B-OSE_Labeled_AE
volume I-OSE_Labeled_AE
contraction I-OSE_Labeled_AE
. O

Symptomatic O
hypotension B-OSE_Labeled_AE
can O
occur O
after O
initiating O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
particularly O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
( O
eGFR B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
elderly O
patients O
, O
patients O
on O
either O
diuretics O
or O
medications O
that O
interfere O
with O
the O
renin-angiotensin-aldosterone O
system O
( O
e.g. O
, O
angiotensin-converting-enzyme O
[ O
ACE O
] O
inhibitors O
, O
angiotensin O
receptor O
blockers O
[ O
ARBs O
] O
) O
, O
or O
patients O
with O
low B-Not_AE_Candidate
systolic I-Not_AE_Candidate
blood I-Not_AE_Candidate
pressure I-Not_AE_Candidate
. O

Before O
initiating O
INVOKANA O
in O
patients O
with O
one O
or O
more O
of O
these O
characteristics O
, O
volume O
status O
should O
be O
assessed O
and O
corrected O
. O

Monitor O
for O
signs O
and O
symptoms O
after O
initiating O
therapy O
. O

5.3 O
Ketoacidosis O
Reports O
of O
ketoacidosis B-OSE_Labeled_AE
, O
a O
serious O
life-threatening O
condition O
requiring O
urgent O
hospitalization O
have O
been O
identified O
in O
postmarketing O
surveillance O
in O
patients O
with O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
and O
type O
2 O
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
receiving O
sodium O
glucose O
co-transporter-2 O
( O
SGLT2 O
) O
inhibitors O
, O
including O
INVOKANA O
. O

Fatal B-NonOSE_AE
cases O
of O
ketoacidosis B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
INVOKANA O
. O

INVOKANA O
is O
not O
indicated O
for O
the O
treatment O
of O
patients O
with O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
] O
. O

Patients O
treated O
with O
INVOKANA O
who O
present O
with O
signs O
and O
symptoms O
consistent O
with O
severe O
metabolic B-NonOSE_AE
acidosis I-NonOSE_AE
should O
be O
assessed O
for O
ketoacidosis B-NonOSE_AE
regardless O
of O
presenting O
blood O
glucose O
levels O
, O
as O
ketoacidosis B-OSE_Labeled_AE
associated O
with O
INVOKANA O
may O
be O
present O
even O
if O
blood B-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
are I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
2 I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

If O
ketoacidosis B-NonOSE_AE
is O
suspected O
, O
INVOKANA O
should O
be O
discontinued O
, O
patient O
should O
be O
evaluated O
, O
and O
prompt O
treatment O
should O
be O
instituted O
. O

Treatment O
of O
ketoacidosis B-NonOSE_AE
may O
require O
insulin O
, O
fluid O
and O
carbohydrate O
replacement O
. O

In O
many O
of O
the O
postmarketing O
reports O
, O
and O
particularly O
in O
patients O
with O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
the O
presence O
of O
ketoacidosis B-NonOSE_AE
was O
not O
immediately O
recognized O
and O
institution O
of O
treatment O
was O
delayed O
because O
presenting O
blood B-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
were I-NonOSE_AE
below I-NonOSE_AE
those O
typically O
expected O
for O
diabetic B-NonOSE_AE
ketoacidosis I-NonOSE_AE
( O
often O
less O
than O
250 O
mg/dL O
) O
. O

Signs O
and O
symptoms O
at O
presentation O
were O
consistent O
with O
dehydration B-NonOSE_AE
and O
severe O
metabolic B-NonOSE_AE
acidosis I-NonOSE_AE
and O
included O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
generalized B-NonOSE_AE
malaise I-NonOSE_AE
, O
and O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
. O

In O
some O
but O
not O
all O
cases O
, O
factors O
predisposing O
to O
ketoacidosis B-NonOSE_AE
such O
as O
insulin O
dose O
reduction O
, O
acute B-Not_AE_Candidate
febrile I-Not_AE_Candidate
illness I-Not_AE_Candidate
, O
reduced O
caloric O
intake O
due O
to O
illness O
or O
surgery O
, O
pancreatic B-Not_AE_Candidate
disorders I-Not_AE_Candidate
suggesting O
insulin B-Not_AE_Candidate
deficiency I-Not_AE_Candidate
( O
e.g. O
, O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
history O
of O
pancreatitis B-Not_AE_Candidate
or O
pancreatic O
surgery O
) O
, O
and O
alcohol O
abuse O
were O
identified O
. O

Before O
initiating O
INVOKANA O
, O
consider O
factors O
in O
the O
patient O
history O
that O
may O
predispose O
to O
ketoacidosis B-NonOSE_AE
including O
pancreatic B-Not_AE_Candidate
insulin I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
from O
any O
cause O
, O
caloric O
restriction O
, O
and O
alcohol O
abuse O
. O

In O
patients O
treated O
with O
INVOKANA O
consider O
monitoring O
for O
ketoacidosis B-NonOSE_AE
and O
temporarily O
discontinuing O
INVOKANA O
in O
clinical O
situations O
known O
to O
predispose O
to O
ketoacidosis B-NonOSE_AE
( O
e.g. O
, O
prolonged O
fasting O
due O
to O
acute B-NonOSE_AE
illness I-NonOSE_AE
or O
surgery O
) O
. O

5.4 O
Acute O
Kidney O
Injury O
and O
Impairment O
in O
Renal O
Function O
INVOKANA O
causes O
intravascular B-OSE_Labeled_AE
volume I-OSE_Labeled_AE
contraction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
and O
can O
cause O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
some O
requiring O
hospitalization O
and O
dialysis B-NonOSE_AE
, O
in O
patients O
receiving O
INVOKANA O
; O
some O
reports O
involved O
patients O
younger O
than O
65 O
years O
of O
age O
. O

Before O
initiating O
INVOKANA O
, O
consider O
factors O
that O
may O
predispose O
patients O
to O
acute B-NonOSE_AE
kidney I-NonOSE_AE
injury I-NonOSE_AE
including O
hypovolemia B-Not_AE_Candidate
, O
chronic B-Not_AE_Candidate
renal I-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
and O
concomitant O
medications O
( O
diuretics O
, O
ACE O
inhibitors O
, O
ARBs O
, O
NSAIDs O
) O
. O

Consider O
temporarily O
discontinuing O
INVOKANA O
in O
any O
setting O
of O
reduced O
oral O
intake O
( O
such O
as O
acute B-NonOSE_AE
illness I-NonOSE_AE
or O
fasting O
) O
or O
fluid B-NonOSE_AE
losses I-NonOSE_AE
( O
such O
as O
gastrointestinal B-NonOSE_AE
illness I-NonOSE_AE
or O
excessive O
heat O
exposure O
) O
; O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
acute B-NonOSE_AE
kidney I-NonOSE_AE
injury I-NonOSE_AE
. O

If O
acute B-NonOSE_AE
kidney I-NonOSE_AE
injury I-NonOSE_AE
occurs O
, O
discontinue O
INVOKANA O
promptly O
and O
institute O
treatment O
. O

INVOKANA O
increases B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
and O
decreases B-OSE_Labeled_AE
eGFR I-OSE_Labeled_AE
. O

Patients O
with O
hypovolemia B-Not_AE_Candidate
may O
be O
more O
susceptible O
to O
these O
changes O
. O

Renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
can O
occur O
after O
initiating O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Renal O
function O
should O
be O
evaluated O
prior O
to O
initiation O
of O
INVOKANA O
and O
monitored O
periodically O
thereafter O
. O

Dosage O
adjustment O
and O
more O
frequent O
renal O
function O
monitoring O
are O
recommended O
in O
patients O
with O
an B-Not_AE_Candidate
eGFR I-Not_AE_Candidate
below I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 O
. O

Use O
of O
INVOKANA O
is O
not O
recommended O
when O
eGFR B-Not_AE_Candidate
is I-Not_AE_Candidate
persistently I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
4 I-Not_AE_Candidate
5 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
and O
is O
contraindicated O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Contraindications O
( O
4 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.5 O
Hyperkalemia O
INVOKANA O
can O
lead O
to O
hyperkalemia B-OSE_Labeled_AE
. O

Patients O
with O
moderate B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
who O
are O
taking O
medications O
that O
interfere O
with O
potassium O
excretion O
, O
such O
as O
potassium-sparing O
diuretics O
, O
or O
medications O
that O
interfere O
with O
the O
renin-angiotensin-aldosterone O
system O
are O
at O
an O
increased O
risk O
of O
developing O
hyperkalemia B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
serum O
potassium O
levels O
periodically O
after O
initiating O
INVOKANA O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
and O
in O
patients O
predisposed O
to O
hyperkalemia B-NonOSE_AE
due O
to O
medications O
or O
other O
medical O
conditions O
. O

5.6 O
Urosepsis O
and O
Pyelonephritis O
There O
have O
been O
postmarketing O
reports O
of O
serious O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
including O
urosepsis B-OSE_Labeled_AE
and O
pyelonephritis B-OSE_Labeled_AE
requiring O
hospitalization O
in O
patients O
receiving O
SGLT2 O
inhibitors O
, O
including O
INVOKANA O
. O

Treatment O
with O
SGLT2 O
inhibitors O
increases O
the O
risk O
for O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Evaluate O
patients O
for O
signs O
and O
symptoms O
of O
urinary B-NonOSE_AE
tract I-NonOSE_AE
infections I-NonOSE_AE
and O
treat O
promptly O
, O
if O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.7 O
Hypoglycemia O
with O
Concomitant O
Use O
with O
Insulin O
and O
Insulin O
Secretagogues O
Insulin O
and O
insulin O
secretagogues O
are O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
. O

INVOKANA O
can O
increase O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
combined O
with O
insulin O
or O
an O
insulin O
secretagogue O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Therefore O
, O
a O
lower O
dose O
of O
insulin O
or O
insulin O
secretagogue O
may O
be O
required O
to O
minimize O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
used O
in O
combination O
with O
INVOKANA O
. O

5.8 O
Genital O
Mycotic O
Infections O
INVOKANA O
increases O
the O
risk O
of O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Patients O
with O
a O
history O
of O
genital B-Not_AE_Candidate
mycotic I-Not_AE_Candidate
infections I-Not_AE_Candidate
and O
uncircumcised O
males O
were O
more O
likely O
to O
develop O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
and O
treat O
appropriately O
. O

5.9 O
Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
angioedema B-OSE_Labeled_AE
and O
anaphylaxis B-OSE_Labeled_AE
, O
have O
been O
reported O
with O
INVOKANA O
. O

These O
reactions O
generally O
occurred O
within O
hours O
to O
days O
after O
initiating O
INVOKANA O
. O

If O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
occur O
, O
discontinue O
use O
of O
INVOKANA O
; O
treat O
and O
monitor O
until O
signs O
and O
symptoms O
resolve O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
. O

5.10 O
Bone O
Fracture O
An O
increased O
risk O
of O
bone B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
occurring O
as O
early O
as O
12 O
weeks O
after O
treatment O
initiation O
, O
was O
observed O
in O
patients O
using O
INVOKANA O
. O

Consider O
factors O
that O
contribute O
to O
fracture O
risk O
prior O
to O
initiating O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.11 O
Increases O
in O
Low-Density O
Lipoprotein O
( O
LDL-C O
) O
Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
occur O
with O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
LDL-C O
and O
treat O
if O
appropriate O
after O
initiating O
INVOKANA O
. O

5.12 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk O
reduction O
with O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

